{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:28:56Z","timestamp":1777570136576,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008078","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000}}],"reference-count":88,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008078.pub2","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T19:58:40Z","timestamp":1328903920000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Alemtuzumab for patients with chronic lymphocytic leukaemia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Nicole","family":"Skoetz","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Bauer","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Elter","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Roloff","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit; Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"10.1002\/14651858.CD008078.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","article-title":"FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia","volume":"13","author":"Demko","year":"2008","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Dmoszynska A Fetni R Wang Y Belkaci M Sirard C Goldberg M Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2006 361","DOI":"10.1200\/jco.2006.24.18_suppl.6601"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0003|cit3","unstructured":"Genzyme A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (ClinicalTrials.gov identifier: NCT00046683) http:\/\/www.clinicaltrials.gov 2003"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Hillmen P Skotnicki A Robak T Jaksic B Dmoszynka A Sirard C Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2006 339","DOI":"10.1200\/jco.2006.24.18_suppl.6511"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Hillmen P Skotnicki A Robak T Jaksic B Sirard C Mayer J Alemtuzumab (Campath, MabCampath) Has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [Abstract] Blood 2006 93","DOI":"10.1182\/blood.V108.11.301.301"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0006|cit6","first-page":"45","article-title":"Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia [Abstract] 1996","volume":"92","author":"Hillmen","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Hillmen P Skotnicki AB Robak T Mayer J Jaksic B Vukovic V Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia Blood 2004 687a","DOI":"10.1182\/blood.V104.11.2505.2505"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0009|cit9","first-page":"381","article-title":"Preliminary results for the phase III trial of alemtuzumab (Campath, MabCampath) vs chlorambucil as first-line treatment for B-cell chronic lymphocytic leukemia (B-cll) [Abstract]","volume":"91","author":"Hillmen","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Mayer J Robak T Skotnicki A Jaksic B Dmoszynka A Sirard C Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2007 365","DOI":"10.1200\/jco.2007.25.18_suppl.7035"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0011|cit11","first-page":"28","article-title":"Interim safety summary of alemtuzumab (Campath, Mabcampath) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia [abstract]","volume":"5","author":"Mayer","year":"2004","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Robak T Dmoszynska A Fetni R Wang Y Belkacz M Sirard C Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (Campath, MabCampath) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL) Blood 2006","DOI":"10.1182\/blood.V108.11.2092.2092"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0013|cit13","first-page":"46","article-title":"Cytogenic abnormalities and associated efficacy from a phase iii study comparing alemtuzumab vs. Chlorambucil as first line therapy for b-cell chronic leukemia [Abstract] 1997","volume":"92","author":"Robak","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Robak T Skotnicki AB Mayer J Vukovic V Weitman S Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2004 571","DOI":"10.1200\/jco.2004.22.90140.6563"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0015|cit15","first-page":"439a","article-title":"Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307)","volume":"102","author":"Skotnicki","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0016|cit16","unstructured":"Elter T Gercheva-Kyuchukova L Pylylpenko H Robak T Jaksic B Rekhtman G Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial The Lancet Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0017|cit17","first-page":"Suppl 2","article-title":"Fludarabine (Flu) plus alemtuzumab (FluCam) improves progression free survival versus fludarabine in previously treated chronic lymphocytic leukemia and demonstrates activity in high risk patients","volume":"95","author":"Engert","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood.V116.21.919.919","article-title":"Overall survival advantage and acceptable safety profile with fludarabine in combination with alemtuzumab (FluCam) in previously treated patients with advanced stage chronic lymphocytic leukemia","volume":"116","author":"Engert","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood.V114.22.537.537","article-title":"Improved progression-free survival (PFS) of alemtuzumab (Campath, MabCampath) plus fludarabine (Fludara) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial","volume":"114","author":"Engert","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.V114.22.538.538","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL) : experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL\/MW) and the \"Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang\" (GOELAMS) : CLL2007FMP (for fit medically patients)","volume":"114","author":"Lepretre","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood.V116.21.698.698","article-title":"CLL2007FMP, a phase III randomized multicentric trial of the French Cooperative Group on CLL and WM (FCGCLL\/MW) and the \"Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang\" (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD","volume":"116","author":"Remi","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Ritgen M Schweighofer C Fingerle-Rowson G Eichhorst B Busch R Stilgenbauer S Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions update on a randomized phase III trial of the German CLL Study Group (GCLLSG) Blood 2004 687a","DOI":"10.1182\/blood.V104.11.2506.2506"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V108.11.33.33","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract]","volume":"108","author":"Schweighofer","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0025|cit25","first-page":"28","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - update on a randomized phase III trial of the German CLL Study Group (GSLLSG)","volume":"27","author":"Schweighofer","year":"2004","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0026|cit26","first-page":"579","article-title":"High efficacy but considerable toxicity of campath-1H consolidation therapy in CLL patients responding to fludarabine - results of a randomized phase III trial [abstract]","volume":"22","author":"Wendtner","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0027|cit27","first-page":"676","article-title":"Consolidiation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"102","author":"Wendtner","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0029|cit29","first-page":"173","article-title":"High efficacy but considerable toxicity of Alemtuzumab (MabCampath) consolidation therapy in CLL patients responding to Fludarabine or Fludarabine\/cyclophosphamide - results of a randomized phase III trial of the GCLLSG","volume":"26","author":"Wendtner","year":"2003","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0030|cit30","first-page":"Suppl","article-title":"High efficacy but considerable toxicity of alemtuzumab (Campath-1H) consolidation therapy in CLL patients responding to fludarabine - results of a randomized phase III trial of the GCLLSG [abstract: 0610]","volume":"88","author":"Wendtner","year":"2003","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V106.11.5046.5046","article-title":"Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study [abstract]","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(03)01327-5","article-title":"Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy","volume":"5","author":"Bolli","year":"2004","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.13379","article-title":"Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"94","author":"Elter","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.24958","article-title":"Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.[Erratum appears in Cancer. 2010 Aug 15;116(16):3982 Note: Dosage error in article text]","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404435","article-title":"Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation","volume":"20","author":"Karlsson","year":"2006","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0038|cit38","first-page":"201","article-title":"Campath - 1h therapy does not affect pbsc collection and engraftment in patients with CLL previously treated with fludarabine [abstract]","volume":"1","author":"Kennedy","year":"2000","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101","volume":"28","author":"Lin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","article-title":"Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia","volume":"93","author":"Osterborg","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.leu.2404265","article-title":"Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects","volume":"20","author":"Pettitt","year":"2006","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0042|cit42","unstructured":"Alemtuzumab + rituximab consolidation in CLL (NCT00771602) Ongoing study August 2008"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0043|cit43","unstructured":"Low dose alemtuzumab for consolidation and maintenance of patients with B-cell CLL (NCT00336206) Ongoing study"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0044|cit44","unstructured":"Subcutaneous alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) in relapsed\/refractory B-CLL Ongoing study"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0045|cit45","unstructured":"CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with CLL who have responded to previous therapy (ISRCTN63375144) Ongoing study June 2008"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0046|cit46","unstructured":"Fludarabine combined with either alemtuzumab or rituximab in treating patients with refractory or relapsed B-CLL (NCT00086775) Ongoing study July 2003"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0047|cit47","unstructured":"A randomised phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab (ISRCTN25180151) Ongoing study December 2005"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0048|cit48","unstructured":"SCH 727965 in patients with mantle cell lymphoma or B-CLL (study P04715AM2) (NCT00871546) Ongoing study March 2009"},{"issue":"1","key":"10.1002\/14651858.CD008078.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leukemia and Lymphoma"},{"issue":"8","key":"10.1002\/14651858.CD008078.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008078.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","article-title":"Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes","volume":"10","author":"Coles","year":"2011","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/leu.2009.148","article-title":"Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study","volume":"23","author":"Cortelezzi","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0054|cit54","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Deeks","year":"2011"},{"issue":"26","key":"10.1002\/14651858.CD008078.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008078.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"issue":"28","key":"10.1002\/14651858.CD008078.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-008-0566-9","article-title":"Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"88","author":"Elter","year":"2009","journal-title":"Annals of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD008078.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD008078.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/JCO.2007.13.7810","article-title":"Have we forgotten the purpose of phase III studies?","volume":"25","author":"Flynn","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0061|cit61","volume-title":"Alemtuzumab in chronic lymphocytic leukemia: a clinical practice guideline. Program in Evidence-based Care. Evidence-based series","volume":"6-16","author":"Fraser","year":"2006"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0062|cit62","unstructured":"Jan B Andrew O Holger S GRADEpro. Version 3.2 for Windows 2008"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.23271","article-title":"Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network","volume":"112","author":"Hainsworth","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD008078.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Hallek M Fingerle-Rowson G Fink A Busch R Mayer J Hensel M Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) ASH Conference Proceedings 2008 abstract 325","DOI":"10.1182\/blood.V112.11.325.325"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0066|cit66","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (March 2011)","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0067|cit67","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0068|cit68","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"issue":"35","key":"10.1002\/14651858.CD008078.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12032-010-9478-3","article-title":"Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia","volume":"28","author":"Kaufman","year":"2011","journal-title":"Med Oncol"},{"issue":"10","key":"10.1002\/14651858.CD008078.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0072|cit72","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Lefebvre","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD008078.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"13","key":"10.1002\/14651858.CD008078.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD008078.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008078.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0077|cit77","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0078|cit78","article-title":"Chapter 11: Presenting results and 'Summary of findings tables'","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Schnemann","year":"2011"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0079|cit79","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sterne","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD008078.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004270.pub2","article-title":"Purine antagonists for chronic lymphocytic leukaemia","author":"Steurer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD008078.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008078.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"10.1002\/14651858.CD008078.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008079","article-title":"Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia","author":"Weingart","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008078.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"issue":"26","key":"10.1002\/14651858.CD008078.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1200\/JCO.2005.05.008","article-title":"Novel immune-based treatment strategies for chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008078.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.21554","article-title":"A retrospective comparison of three sequential groups of patients with recurrent\/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens","volume":"106","author":"Wierda","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008078.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.25379","article-title":"Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Cancer"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008078.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:52:39Z","timestamp":1722415959000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008078.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008078.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}